Source:http://linkedlifedata.com/resource/pubmed/id/12851678
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2003-7-9
|
pubmed:abstractText |
The serum level of beta1,4-galactosyltransferase (beta1,4-GalT) is increased in both malignancy and benign diseases. Galactosyltransferase associated with tumor (GAT) is one of the soluble forms of beta1,4-GalT, and is a marker of ovarian cancer with a high specificity. GAT and normal soluble beta1,4-GalT are both derived from the same membrane-bound form of the enzyme. This study investigated the mechanism of GAT elevation in patients with ovarian cancer. The serum levels of GAT and normal beta1,4-GalT were measured using specific monoclonal antibodies. In addition, nude mice bearing human ovarian cancer were used to assess the kinetics of tumor-derived enzymes. GAT and normal beta1,4-GalT were both detected in ovarian cancer patients, but only GAT reflected the tumor status. In tumor-bearing nude mice, both soluble forms of beta1,4-GalT were released from tumor cells, but the half-life of GAT was far shorter than that of normal beta1,4-GalT. Addition of serum from healthy women to colostrum (which has a high GAT content) reduced the GAT level, while adding patient serum caused a significantly smaller reduction of GAT. Addition of the serum from mouse which includes no human beta1,4-GalT to colostrum also reduced the GAT level with no significant change of total soluble beta1,4-GalT. These findings indicate that human serum contains certain factors that decrease the GAT level, but these factors are inhibited in ovarian cancer patients so that a high GAT level persists. It seems that the decrease of GAT occurs as a result of conversion into normal beta1,4-GalT.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1019-6439
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
303-10
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12851678-Animals,
pubmed-meshheading:12851678-Blotting, Northern,
pubmed-meshheading:12851678-Colostrum,
pubmed-meshheading:12851678-Female,
pubmed-meshheading:12851678-Galactosyltransferases,
pubmed-meshheading:12851678-Humans,
pubmed-meshheading:12851678-Immunoenzyme Techniques,
pubmed-meshheading:12851678-Mice,
pubmed-meshheading:12851678-Mice, Inbred BALB C,
pubmed-meshheading:12851678-Mice, Nude,
pubmed-meshheading:12851678-Middle Aged,
pubmed-meshheading:12851678-N-Acetyllactosamine Synthase,
pubmed-meshheading:12851678-Neoplasms, Experimental,
pubmed-meshheading:12851678-Ovarian Neoplasms,
pubmed-meshheading:12851678-RNA, Messenger,
pubmed-meshheading:12851678-Tumor Cells, Cultured,
pubmed-meshheading:12851678-Tumor Markers, Biological
|
pubmed:year |
2003
|
pubmed:articleTitle |
Galactosyltransferase associated with tumor in patients with ovarian cancer: factors involved in elevation of serum galactosyltransferase.
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|